Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MTCR

Metacrine (MTCR) Stock Price, News & Analysis

Metacrine logo

About Metacrine Stock (NASDAQ:MTCR)

Advanced Chart

Key Stats

Today's Range
$0.58
$0.59
50-Day Range
$0.55
$0.59
52-Week Range
$0.30
$0.59
Volume
83,889 shs
Average Volume
225,834 shs
Market Capitalization
$24.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Receive MTCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter.

MTCR Stock News Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
See More Headlines

MTCR Stock Analysis - Frequently Asked Questions

Metacrine, Inc. (NASDAQ:MTCR) released its earnings results on Thursday, May, 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.06.

Metacrine (MTCR) raised $84 million in an initial public offering (IPO) on Wednesday, September 16th 2020. The company issued 6,500,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Metacrine investors own include Outlook Therapeutics (OTLK), Plug Power (PLUG), Advanced Micro Devices (AMD), Salesforce (CRM), Fisker (FSR), Micron Technology (MU) and 9 Meters Biopharma (NMTR).

Company Calendar

Last Earnings
5/13/2021
Today
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MTCR
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-62,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.36 per share
Price / Book
0.43

Miscellaneous

Free Float
36,695,000
Market Cap
$24.75 million
Optionable
Not Optionable
Beta
-0.73
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:MTCR) was last updated on 5/9/2025 by MarketBeat.com Staff
From Our Partners